Remove: Clinical Study on the Effectiveness and Safety Evaluation of Directional Atherectomy Combined With Drug-coated Balloons

Sponsor
Second Affiliated Hospital of Soochow University (Other)
Overall Status
Recruiting
CT.gov ID
NCT04986098
Collaborator
(none)
240
1
29
8.3

Study Details

Study Description

Brief Summary

DCB can maximize the patency rate of blood vessels on the basis of intraluminal DA. DA+DCB treatment is effective and safe [8], and the advantages of DA and DCB in the treatment of severe calcification and occlusive disease across joints and lower extremities have been confirmed. The combined application of DA and DCB in the treatment of peripheral arterial disease has a good early and mid-term effect. Konstantinos et al. reported that DARRT has a higher first-phase patency rate compared with DCB. A retrospective study by Sebastian et al. showed that compared with PTA after DA, the combination of DA and DCB has a better event-free survival rate after 12 months of follow-up. Therefore, DA combined with DCB therapy may be one of the best and most promising methods for the treatment of lower extremity ASO.

Condition or Disease Intervention/Treatment Phase

Study Design

Study Type:
Observational [Patient Registry]
Anticipated Enrollment :
240 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Clinical Study on the Effectiveness and Safety Evaluation of Directional Atherectomy Combined With Drug-coated Balloons in the Treatment of Femoral Popliteal Artery Occlusion
Anticipated Study Start Date :
Aug 1, 2021
Anticipated Primary Completion Date :
Dec 31, 2022
Anticipated Study Completion Date :
Dec 31, 2023

Outcome Measures

Primary Outcome Measures

  1. Primary vascular patency rate [24 months]

    Free-Target lesion reconstruction rate(F-TLR)at 24 months after operation

  2. Major adverse event [24 months]

    MAE within 24 months after surgery

Secondary Outcome Measures

  1. Quality of life assessment [24 months]

    Quality of life assessment (VAS-QOL) after discharge, 1, 3, 6, 12, and 24 months after operation

  2. ABI [24 months]

    Ankle-brachial index (ABI) at discharge, 1, 3, 6, 12, and 24 months after operation

  3. Rutherford classification [24 months]

    Discharge, 1, 3, 6, 12, and 24 months after the Rutherford classification

  4. TLR [24 months]

    The incidence of TLR after discharge, 1, 3, 6, 12, and 24 months

  5. TVR [24 months]

    The incidence of TVR after discharge, 1, 3, 6, 12, and 24 months

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Age over 18 years old

  • Ruthford grade 2-5 patients

  • For patients whose arteries in both lower extremities meet the enrollment criteria, both lower extremities can be included

  • At least one outflow tract over 10 cm at the distal end of the knee is continuous with a healthy back of the foot or internal and external arteries of the plantar

  • The guide wire clearly passed through the lesion and the follow-up treatment was performed. In the case of failed anterograde passage, reverse puncture to achieve the guide wire through the lesion can also be included in the group

  • After the failure of the first intracavitary treatment, the blood vessel can be recanalized by the intracavitary treatment again, and it can still be included in the group

  • Patients with aortic iliac artery disease can be included in the group after the aortic artery is opened

  • Patients who are willing to participate in this study and sign informed consent

  • For severely infected R6 patients, if the infection is effectively controlled, they can be considered for inclusion

Exclusion Criteria:
  • Patients who refuse to participate in this observational study

  • Femoral popliteal artery disease with acute and subacute thrombosis

  • Patients with thromboangiitis

  • Patients who have failed endovascular treatment and transferred to surgical treatment

  • For patients who have received plaque exfoliation on the femoral artery

  • Patients who are allergic to heparin, low molecular weight heparin and contrast agents

  • Patients enrolled in other clinical studies in the past 3 months

  • Pregnant women

  • Patients who have a life span of less than 2 years due to serious diseases

Contacts and Locations

Locations

Site City State Country Postal Code
1 the Second Affiliated Hospital of Soochow University Suzhou Jiangsu China 215000

Sponsors and Collaborators

  • Second Affiliated Hospital of Soochow University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Second Affiliated Hospital of Soochow University
ClinicalTrials.gov Identifier:
NCT04986098
Other Study ID Numbers:
  • Hongfei Sang
First Posted:
Aug 2, 2021
Last Update Posted:
Aug 2, 2021
Last Verified:
Jul 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
Yes
Studies a U.S. FDA-regulated Device Product:
Yes
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 2, 2021